Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
31 January 2018
E-000561-18
Question for written answer
to the Commission
Rule 130
Monika Beňová (S&D)

 Subject:  European Medicines Agency
 Answer(s) 

Reports that the European Medicines Agency (EMA) will not be ready by the conclusion of the process for the UK’s withdrawal from the European Union are increasing in frequency. It is becoming quite clear that there could be some, or even significant, disruption of the operational capacity of this agency, one of the most important currently operating in the European Union. Its involvement in overseeing the safety and effectiveness of all new drugs entering the European Union makes any disruption of its operations a serious issue.

Does the Commission have any information available to clarify the situation regarding the expected preparedness of the Amsterdam site?

If it becomes apparent that significant disruption is certain to occur, will the Commission take measures to avoid such an outcome?

If it is already clear that disruption will occur, will the Commission assist in efforts to mitigate such a state of affairs?

Last updated: 13 February 2018Legal notice